<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0405">
 <label>20</label>
 <element-citation publication-type="journal" id="sbref0405">
  <person-group person-group-type="author">
   <name>
    <surname>Mahaffey</surname>
    <given-names>K.W.</given-names>
   </name>
   <name>
    <surname>Meg</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Jardine</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Bompoint</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Cannon</surname>
    <given-names>C.P.</given-names>
   </name>
   <name>
    <surname>Neal</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Heerspink</surname>
    <given-names>H.J.L.</given-names>
   </name>
   <collab>On behalf of the CREDENCE Study Investigators</collab>
  </person-group>
  <article-title>Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Results from the randomized CREDENCE trial</article-title>
  <source>Circulation</source>
  <volume>140</volume>
  <year>2019</year>
  <fpage>739</fpage>
  <lpage>750</lpage>
  <pub-id pub-id-type="pmid">31291786</pub-id>
 </element-citation>
</ref>
